Indian Firm Seeks To Prove New Drugs Can Be Developed Cheaply
This article was originally published in PharmAsia News
Executive Summary
An investment company in India has poured more than $61 million into five companies as part of an effort to prove drug development can be done more cheaply than is the practice today. Nadathur Holdings and Investments says it seeks to disprove the assumption new-drug development requires as much as $1 billion. Nadathur has created Lifespring Ventures as a subsidiary, now owner itself of five start-up firms in the drug-discovery process. The firms operate as stand-alone companies trying to find treatments focusing on metabolic syndrome connected to heart, stroke and diabetes conditions. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.